Skip to content
10-Q

Quarterly Report

CENTESSA PHARMACEUTICALS PLC CNTA

0001847903-25-000072

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 133.62M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $109.25M
Long Term Debt Q1 2025 · Dec 31, 2024 $108.94M
Short Term Investments Q1 2025 · Mar 31, 2025 $179.35M
Short Term Investments Q1 2025 · Dec 31, 2024 $98.96M
Current Liabilities Q1 2025 · Mar 31, 2025 $24.2M
Current Liabilities Q1 2025 · Dec 31, 2024 $58M
Total Liabilities Q1 2025 · Mar 31, 2025 $141.6M
Total Liabilities Q1 2025 · Dec 31, 2024 $175.25M
Current Assets Q1 2025 · Mar 31, 2025 $347.72M
Current Assets Q1 2025 · Dec 31, 2024 $536.41M
Total Assets Q1 2025 · Mar 31, 2025 $527.85M
Total Assets Q1 2025 · Dec 31, 2024 $576.8M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $383.22M
Shares Diluted Q1 2025 · Mar 31, 2024 99.89M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$37.29M
Stockholders Equity Q1 2025 · Mar 31, 2024 $215.16M
Stockholders Equity Q1 2025 · Dec 31, 2023 $236.24M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.38
Eps Basic Q1 2025 · Mar 31, 2024 −$0.38
Sga Expense Q1 2025 · Mar 31, 2024 $13.44M
Net Income Q1 2025 · Mar 31, 2024 −$38.05M
Operating Income Q1 2025 · Mar 31, 2024 −$36.09M
Revenue Q1 2025 · Mar 31, 2024 $0